Prevention of the Meningococcal Disease

1 clinical trials · Condition

Record	Firm	Date
A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. (NCT01911221)	Novartis Vaccines	2013-08-01

Every clearance here is in the API, with alerts when new ones post.